Laden…
8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Triazolam is a short-acting benzodiazepine with hypnotic effects, primarily used for the treatment of sleep disorders. It acts by enhancing GABAergic inhibition in the central nervous system. Due to its mechanism of action, dependence and withdrawal symptoms may occur. The substance should be used with caution, especially with prolonged use.
Receptor Targets
Mechanism of Action
Designations
IUPAC: 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der GABA-A-Rezeptor ist ein ligandengesteuerter Chloridkanal und der wichtigste inhibitorische Rezeptor im zentralen Nervensystem. Er besitzt multiple allosterische Bindungsstellen für verschiedene Substanzklassen.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Triazolam ist ein ultrakurz wirksames Triazolobenzodiazepin mit der kürzesten Halbwertszeit aller zugelassenen Benzodiazepine (1.5-5.5h). Positiv-allosterischer Modulator an GABAA-Rezeptoren an der Benzodiazepinbindungsstelle. Die Triazol-Ringstruktur (gemeinsam mit Alprazolam) verleiht neben dem klassischen Benzodiazepin-Profil ausgeprägtere euphorische Eigenschaften. CYP3A4-Substrat — signifikante pharmakokinetische Interaktionen mit CYP3A4-Inhibitoren (Azol-Antimykotika, HIV-Proteasehemmer, Grapefruitsaft erhöhen die Triazolam-Exposition erheblich). Die extrem kurze Halbwertszeit erzeugt intensive anterograde Amnesie ohne prolongierte Sedierung — dieses Profil macht Triazolam besonders gefährlich als K.O.-Substanz. Charakteristisch ist zudem ausgeprägtes Rebound-Phänomen: Rebound-Insomnie und Angst noch in der zweiten Nachthälfte nach abendlicher Einnahme (Rückkehr von Entzugssymptomen innerhalb einer Einzeldosierungsperiode bei kurzer Halbwertszeit).
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Total duration 6-8 hours
Peak
1-2 hours
Onset
15-30 minutes
Total duration
6-8 hours
After effects
Fatigue, drowsiness
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Neurotoxicity
possible
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.